American Association for Cancer Research
Browse
15417786mcr170028-sup-177609_0_supp_3827392_rsxlz2.pdf (426.18 kB)

Supplementary Figures 1-4 from CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC

Download (426.18 kB)
journal contribution
posted on 2023-04-03, 17:42 authored by James P. Stice, Suzanne E. Wardell, John D. Norris, Alexander P. Yllanes, Holly M. Alley, Victoria O. Haney, Hannah S. White, Rachid Safi, Peter S. Winter, Kimberly J. Cocce, Rigel J. Kishton, Scott A. Lawrence, Jay C. Strum, Donald P. McDonnell

Supplemental Figure 1. The effects of G1T28 are due to CDK4/6 inhibition. Supplemental Figure 2. Analysis of pharmacodynamics endpoints indicates on-target activity in 22Rv1 tumors. A. Supplemental Figure 3. G1T38 and G128 have similar in vitro efficacy. Supplemental Figure 4. G1T28 inhibits anti-androgen stimulated prostate cancer cell growth.

Funding

G1 Therapeutics

History

ARTICLE ABSTRACT

Resistance to second-generation androgen receptor (AR) antagonists and CYP17 inhibitors in patients with castration-resistant prostate cancer (CRPC) develops rapidly through reactivation of the androgen signaling axis and has been attributed to AR overexpression, production of constitutively active AR splice variants, or the selection for AR mutants with altered ligand-binding specificity. It has been established that androgens induce cell-cycle progression, in part, through upregulation of cyclin D1 (CCND1) expression and subsequent activation of cyclin-dependent kinases 4 and 6 (CDK4/6). Thus, the efficacy of the newly described CDK4/6 inhibitors (G1T28 and G1T38), docetaxel and enzalutamide, was evaluated as single agents in clinically relevant in vitro and in vivo models of hormone-sensitive and treatment-resistant prostate cancer. CDK4/6 inhibition (CDK4/6i) was as effective as docetaxel in animal models of treatment-resistant CRPC but exhibited significantly less toxicity. The in vivo effects were durable and importantly were observed in prostate cancer cells expressing wild-type AR, AR mutants, and those that have lost AR expression. CDK4/6i was also effective in prostate tumor models expressing the AR-V7 variant or the AR F876L mutation, both of which are associated with treatment resistance. Furthermore, CDK4/6i was effective in prostate cancer models where AR expression was lost. It is concluded that CDK4/6 inhibitors are a viable alternative to taxanes as therapeutic interventions in endocrine therapy–refractory CRPC.Implications: The preclinical efficacy of CDK4/6 monotherapy observed here suggests the need for near-term clinical studies of these agents in advanced prostate cancer. Mol Cancer Res; 15(6); 660–9. ©2017 AACR.

Usage metrics

    Molecular Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC